Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
A legfontosabb adatok
- Ki végzi
- UMC Utrecht
- Hol
- Ann Arbor, Augusta, Chicago, Columbus, Jacksonville, New Orleans, New York, Pittsburgh, Portland, Providence és Winston-Salem (Egyesült Államok)Mind a 11 helyszín megnézéseMég 28 másik országban, 397 helyszínen
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 20 000 fő, tervezett
- Kezdés
- 2016. ápr. 11.
- Várható befejezés
- 2029. febr.
- A vizsgálat típusa
- Beavatkozással járó, 19 csoport
- A vizsgált kezelések
- Ceftriaxone + Macrolide
- Moxifloxacin or Levofloxacin
- Piperacillin-tazobactam + Macrolide
- Ceftaroline + Macrolide
- Amoxicillin-clavulanate + Macrolide
- Standard course macrolide
- Extended course macrolide
- No systemic corticosteroid
- Fixed-duration Hydrocortisone
- Shock-dependent hydrocortisone
- Fixed-duration higher dose Hydrocortisone
- No antiviral agent for influenza
- Five-days oseltamivir
- Ten-days oseltamivir
- No antiviral agent for COVID-19
- Lopinavir / Ritonavir
- Hydroxychloroquine
- Hydroxychloroquine + lopinavir/ritonavir
- Ivermectin
- No immune modulation for COVID-19
- Interferon beta-1a
- Anakinra
- Tocilizumab
- Sarilumab
- Local standard venous thromboprophylaxis
- Therapeutic dose anticoagulation
- Conventional low dose thromboprophylaxis
- Intermediate dose thromboprophylaxis
- Continuation of therapeutic dose anticoagulation
- No immunoglobulin
- Convalescent plasma
- Delayed administration of convalescent plasma
- No vitamin C
- Vitamin C
- No antiplatelet
- Aspirin
- P2Y12 inhibitor
- No simvastatin
- Simvastatin
- Eritoran
- Apremilast
- Clinician-preferred mechanical ventilation strategy
- Protocolised mechanical ventilation strategy
- No renin-angiotensin system inhibitor
- Angiotensin converting enzyme inhibitor
- Angiotensin Receptor Blockers
- ARB + DMX-200
- No cysteamine
- Cysteamine
- Fixed-duration dexamethasone
- Baloxavir Marboxil
- Five-days oseltamivir + baloxavir marboxil
- Ten-days oseltamivir + baloxavir marboxil
- No endothelial modulator
- Imatinib
- No Immune Modulator for Influenza
- Baricitinib
- Nirmatrelvir/ritonavir
- Remdesivir
- Nirmatrelvir/ritonavir + remdesivir
- A regiszteradat frissítve
- 2026. november 4.
Ki vehet részt
- Életkor
- 28 nap felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Egyéb feltételek
- The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and exclusion criteria that determine eligibility for randomization within the Platform. Another level is that, once eligible for inclusion within the Platform, additional criteria (typically exclusion criteria) are applied that are specific to each domain. Finally, intervention-level eligibility criteria may be applied for interventions within a domain. A patient is eligible for inclusion within a domain when:
- All Platform inclusion criteria are met
- None of the Platform exclusion criteria are met
- Domain-specific eligibility criteria are met
- The patient is eligible for at least two interventions within a domain; As such, the key "inclusion criteria" for being eligible for a domain are that the patient is eligible for the Platform; --; PLATFORM INCLUSION CRITERIA:
- Hospitalised patient
- Acute respiratory tract infection
- Aged 28 days or older; PLATFORM EXCLUSION CRITERIA:
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Patient is expected to be discharged from hospital within the next 24 hours
- Previous participation in this REMAP within the last 90 days; DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:; Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org)
Helyszínek itt: Egyesült Államok
Még 28 másik országban, 397 helyszínen
- University of MichiganAnn Arbor, Egyesült ÁllamokContact: Robert Hyzy, MDRésztvevőt keres
- Augusta UniversityAugusta, Egyesült ÁllamokContact: Jose Vazquez, MDToborzás még nem indult
- University of Illinois HealthChicago, Egyesült ÁllamokContact: Jeffrey Jacobson, MDRésztvevőt keres
- The Ohio State University -Wexner Medical CenterColumbus, Egyesült ÁllamokContact: Matthew Exline, MDRésztvevőt keres
- University of FloridaJacksonville, Egyesült ÁllamokContact: Hadi Hatoum, MDRésztvevőt keres
- Tulane Medical CenterNew Orleans, Egyesült ÁllamokContact: Joshua Denson, MDToborzás még nem indult
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokContact: Stephen Pastores, MDRésztvevőt keres
- University of Pittsburgh Medical CentrePittsburgh, Egyesült ÁllamokContact: Stephanie MongomeryRésztvevőt keres
- Oregon Health and Science UniversityPortland, Egyesült ÁllamokContact: Akram Khankhana, MDRésztvevőt keres
- Brown University/Rhode Island HospitalProvidence, Egyesült ÁllamokContact: Mitchell Levy, MDToborzás még nem indult
- Wake Forest Baptist HealthWinston-Salem, Egyesült ÁllamokContact: Ashish Khanna, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
A teljes eredeti leírásKevesebb
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
A vizsgálat 19 csoportja
- Antibiotic DomainEgyéb csoport
Patients with community-acquired pneumonia and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment.
Kezelés: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide és Amoxicillin-clavulanate + Macrolide
- Macrolide Duration DomainEgyéb csoport
Patients with community-acquired pneumonia who have been allocated to receive a beta-lactam + macrolide intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
Kezelés: Standard course macrolide és Extended course macrolide
- Corticosteroid DomainEgyéb csoport
Patients with severe lower-respiratory tract infection will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. Note: the fixed-course hydrocortisone has been closed to recruitment
Kezelés: No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone és Fixed-duration dexamethasone
- Influenza Antiviral DomainEgyéb csoport
Patients with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
Kezelés: No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil és Ten-days oseltamivir + baloxavir marboxil
- COVID-19 Antiviral DomainEgyéb csoport
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed.
Kezelés: No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir és Ivermectin
- COVID-19 Immune Modulation DomainEgyéb csoport
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed.
Kezelés: No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab és Sarilumab
- Anticoagulation DomainEgyéb csoport
Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.
Kezelés: Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis és Continuation of therapeutic dose anticoagulation
- Immunoglobulin DomainEgyéb csoport
Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients.
Kezelés: No immunoglobulin, Convalescent plasma és Delayed administration of convalescent plasma
- Vitamin C DomainEgyéb csoport
Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed.
Kezelés: No vitamin C és Vitamin C
- Simvastatin DomainEgyéb csoport
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed.
Kezelés: No simvastatin és Simvastatin
- Antiplatelet DomainEgyéb csoport
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor. Note: this domain is now closed.
Kezelés: No antiplatelet, Aspirin és P2Y12 inhibitor
- Mechanical Ventilation DomainEgyéb csoport
Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
Kezelés: Clinician-preferred mechanical ventilation strategy és Protocolised mechanical ventilation strategy
- COVID-19 Immune Modulation (2) DomainEgyéb csoport
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed.
Kezelés: No immune modulation for COVID-19, Eritoran és Apremilast
- ACE2 RAS DomainEgyéb csoport
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed.
Kezelés: No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers és ARB + DMX-200
- Cysteamine DomainEgyéb csoport
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine. Note: this domain is now closed.
Kezelés: No cysteamine és Cysteamine
- Endothelial DomainEgyéb csoport
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
Kezelés: No endothelial modulator és Imatinib
- Influenza Immune ModulationEgyéb csoport
Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
Kezelés: No Immune Modulator for Influenza, Tocilizumab és Baricitinib
- COVID-19 Antiviral (II) DomainEgyéb csoport
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
Kezelés: No antiviral agent for COVID-19, Nirmatrelvir/ritonavir, Remdesivir és Nirmatrelvir/ritonavir + remdesivir
- Tropical Antibiotic DomainEgyéb csoport
Patients with community-acquired pneumonia in regions at locations where or when empiric cover for melioidosis is appropriate, and requiring empiric antibiotic therapy including cover for melioidosis, will be randomised one of two antibiotic interventions
Kezelés: Amoxicillin-clavulanate + Ceftazidime + Macrolide és Meropenem + Macrolide
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Publikációk
- Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.Thorax, 2025
- Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.Intensive care medicine, 2025
- Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.JAMA, 2023
- Simvastatin in Critically Ill Patients with Covid-19.The New England journal of medicine, 2023
- The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.The Journal of infectious diseases, 2023
- Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews, 2023
- Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.JAMA, 2023
- Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.JAMA, 2023
- Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.JAMA, 2022
- Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.JAMA, 2021
- A regiszteradat frissítve
- 2026. november 4.